Key result
Reperfusion plus anticoagulation linked to ~19 percentage-point greater clot resolution vs. anticoagulation alone in PE.
Why the study?
Major progress in reperfusion strategies has substantially improved short-term outcomes in patients with PE, yet up to 50% of patients report persistent dyspnea after acute PE.
Does reperfusion therapy followed by anticoagulation improve clot resolution (vascular obstructive index reduction) and 12-month clinical outcomes compared with anticoagulation alone in patients with acute pulmonary embolism?
Cohort (n=382)
No
Does reperfusion therapy followed by anticoagulation improve clot resolution (vascular obstructive index reduction) and 12-month clinical outcomes compared with anticoagulation alone in patients with acute pulmonary embolism?
In patients with acute pulmonary embolism, reperfusion therapies alongside anticoagulation were associated with greater pulmonary clot resolution, improved right ventricular recovery, fewer readmissions, and lower 1-year post-discharge mortality compared with anticoagulation alone.
Answers are grounded in this paper and cite their sources.
Reperfusion plus anticoagulation was associated with better outcomes in acute PE; hypothesis-generating and requires randomized confirmation.
OBJECTIVE: Major progress in reperfusion strategies has substantially improved the short-term outcomes of patients with pulmonary embolism (PE), however, up to 50% of patients report persistent dyspnea after acute PE. METHODS: A retrospective study of the PE response team registry and included patients with repeat imaging at 3 to 12 months. The primary outcome was to determine the incidence of residual pulmonary vascular obstruction following acute PE. Secondary outcomes included the development of PE recurrence, right ventricular (RV) dysfunction, chronic thromboembolic pulmonary hypertension, readmission, and mortality at 12 months. RESULTS: A total of 382 patients were included, and 107 patients received reperfusion therapies followed by anticoagulation. Patients who received reperfusion therapies including systemic thrombolysis, catheter-directed thrombolysis, and mechanical thrombectomy presented with a higher vascular obstructive index (47% vs 28%; P < .001) and signs of right heart strain on echocardiogram (81% vs 43%; P < .001) at the time of diagnosis. A higher absolute reduction in vascular obstructive index (45% vs 26%; 95% confidence interval, 14.0-25.6; P < .001), greater improvement in RV function (82% vs 65%; P = .021), and lower 12-month mortality rate (2% vs 7%; P = .038) and readmission rate (33% vs 46%; P = .031) were observed in the reperfusion group. No statistically significant differences were found between groups in the development of chronic thromboembolic pulmonary hypertension (8% vs 5%; P = .488) and PE recurrence (8% vs 6%; P = .646). CONCLUSIONS: We observed a favorable survival and greater improvement in clot resolution and RV function in patients treated with reperfusion therapies.
No takes yet. Share an insight, caveat, or question.
Lio et al. (2024) conducted a cohort in Acute pulmonary embolism (PE) (n=382). Reperfusion therapies (full-dose or half-dose systemic thrombolysis with alteplase, catheter-directed thrombolysis, or mechanical thrombectomy) followed by anticoagulation vs. Anticoagulation alone was evaluated on Absolute reduction in pulmonary vascular obstructive index (VOI) / clot resolution on repeat imaging at 3 to 12 months (95% CI 14.0-25.6, p=< .001). Reperfusion therapies plus anticoagulation achieved a greater absolute reduction in vascular obstructive index and lower 12-month mortality than anticoagulation alone.
Synapse has enriched 10 related papers. Consider them for comparative context: